MedTrace Logo

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

NCT02221999 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2023-08-29

No results posted yet for this study

Summary

The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.

In patients with some sub-type advanced breast cancer, neo-adjuvant chemotherapy combined with endocrine therapy may improve the pathological remission rate.

Premenopausal patients with triple negative breast caner and hormonal receptor positve breast cancer patients will be randominzed to have neoadjuvant chemotherapy combined with endocrine therapy or not.

Conditions

  • Tubular Breast Cancer
  • Mucinous Breast Cancer
  • Invasive Ductal Breast Cancer
  • Inflammatory Breast Cancer

Interventions

DRUG

Paclitaxel

DRUG

Cisplatin

DRUG

Gonadotropin-releasing hormone agonist

Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m

DRUG

Letrozole

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jinsong Lu · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2019-01-31
Completion
2029-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221999 on ClinicalTrials.gov